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A B S T R A C T
Purpose: Most common clinical studies with antiepileptic drugs do not reﬂect medical everyday practice
due to their strict in- and exclusion criteria and speciﬁcations of treatment regimens. Here we present a
large non-interventional registry with the intention to evaluate the spectrum of applications in daily use
and the efﬁcacy and tolerability of intravenously given levetiracetam (LEV-iv).
Methods: In a prospective approach of 17 neurological and neuropediatric centres in Germany LEV-iv
treated patients of all ages were included over a period of 10 months. The observational period was 10
days with daily documentation of LEV-iv administration, type and frequency of seizures, currently used
drugs and doses, and adverse events (AEs). In addition, treatment efﬁcacy and tolerability were assessed
by patients and physicians at study end as well as practicability of LEV-iv using a ﬁve-step scale.
Results: In 95 patients LEV-iv was administered, 93 were included into the analysis. The median LEV-iv
dose was 1500 mg (range 110–6000 mg) per day. Median age was 66 years (range 0.7–90.3 years). The
majority of patients (n = 70, 75%) suffered from status epilepticus (SE, n = 55, 59%) and acute seizure
clusters (n = 15, 16%). Of those with SE, 41 patients (75%) had SE for the ﬁrst time. Acute seizure clusters
and SE terminated in 83% after LEV-iv administration. A total of 29 adverse events were reported in 17 of
the 95 patients from the safety set. Ten of these were at least possibly related to LEV-iv treatment. Slight
decrease of blood pressure during the infusion (3 patients each) was captured most frequently. No
serious side effect was observed. Physicians rated the efﬁcacy and tolerability of LEV-iv treatment as
good or very good in 78% and 82% of the cases, respectively.
Contents lists available at ScienceDirect
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remarkable good response and tolerability in patients with acute onset seizures (mostly SE). Further
randomized controlled studies, like the established status epilepticus trial (ESET) are needed to conﬁrm
these ﬁndings.
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In 2006, levetiracetam was approved as the ﬁrst of the newer
anticonvulsive drugs as an intravenous formulation (LEV-iv,
Keppra iv1) for patients with epileptic seizures who are unable
to take oral medications. Levetiracetam is most commonly
approved as adjunctive treatment of partial onset seizures with
or without secondary generalization, other approved indications
include monotherapy treatment of partial onset seizures with or
without secondary generalization, and adjunctive treatment of
myoclonic seizures associated with juvenile myoclonic epilepsy
and primary generalized tonic–clonic seizures associated with
idiopathic generalized epilepsy.
Unlike other antiepileptic drugs (AEDs), the mechanism of
action of levetiracetam appears to involve neuronal binding to
synaptic vesicle protein 2A (SVA2) [1], inhibiting calcium release
from intraneuronal stores, opposing the activity of negative
modulators of GABA- and glycin-gated currents and inhibiting
excessive synchronized activity between neurons [2]. LEV is
characterized by a favourable pharmacokinetic proﬁle with
minimal plasma protein binding, negligible drug interactions
and a lack of hepatic metabolism [3]. The approved LEV-iv
administration appears to be well tolerated even at higher doses
and faster infusion rates (1500–2500 mg administered over 5 min)
[4].
With the introduction of the intravenous preparation of LEV
there has been considerable interest in the use of LEV-iv for the
treatment of status epilepticus (SE), although LEV is not approved
for this indication. The favourable pharmacokinetic and safety
proﬁles make LEV-iv a possible candidate for fast and effective
treatment of SE, when ﬁrst-line agents cannot be applied or do not
work sufﬁciently [3]. First studies, reporting on small sample
studies found LEV-iv to be efﬁcacious in terminating SE in a high
proportion of subjects [5–7]. A meta-analysis of published studies
until 2013 calculated that the mean efﬁcacy of LEV in convulsive
benzodiazepine-resistant status SE was 69% [8].
The aim of the present study conducted as a prospective
registry under normal clinical conditions was to evaluate the
spectrum of application in daily use and the efﬁcacy and
tolerability of intravenously given Levetiracetam over an observa-
tion period of 10 days.
2. Methods
The study was approved by the institutional ethic committee
and was carried out according to the Declaration of Helsinki and
local health regulations. Written informed consent was obtained
from patients before enrolment in the study. If patients were
unable to give consent, consent was requested from their legal
guardian or close relatives.
The study was designed as a prospective non-interventional
observational trial (according to §67.6 AMG [Medicinal Products
Act]) in 17 neurological and neuropediatric centres in Germany
from May 2008 to March 2009. Patients with any type of seizures
or epilepsy syndrome were selected if previous treatment results
were unsatisfactory and anticonvulsant therapy with LEV-iv was
considered.Baseline demographics and disease characteristics as well as
previous and current AED use were recorded in the Case Report
Form (CRF). Seizure frequency and seizure types were captured
during a 4-week retrospective baseline period. Seizures were
classiﬁed according to the International League against Epilepsy
(ILAE) classiﬁcation [9]. SE was deﬁned as ongoing seizures or
seizures without recovery of consciousness or clinical baseline
conditions for at least 30 min.
Treatment, including diagnosis and control, did not follow any
predeﬁned study plan or interventions but only the medical
practice. LEV-iv was administered according to the Summary of
Product Characteristics over a 15 min period. Titration rate and
ﬁnal dose were determined based on the patient’s response to
therapy. The physician determined whether baseline AEDs were
modiﬁed.
The observational period was 10 days with daily documenta-
tion of LEV-iv administration and type and frequency of the
seizures, currently used drugs and doses, and adverse events (AEs).
In addition, patients and physicians assessed treatment efﬁcacy
and tolerability at study end as well as handling of LEV-iv by
physicians using a ﬁve-step scale. Without further operational
deﬁnition patients and physicians were ask to rate efﬁcacy and
tolerability as ‘very good’, ‘good’, ‘satisfactory’, ‘sufﬁcient’ or
‘insufﬁcient’ and physicians were ask to rate handling of LEV-iv and
the conversion to oral LEV treatment as ‘very easy’, ‘easy’, ‘normal’,
‘difﬁcult’ or ‘very difﬁcult’.
Descriptive statistical methods like frequency counts and
summary statistics with arithmetic mean, standard deviation
(SD) and median were used. Adverse events were coded according
to the Medical Dictionary for Regulatory Activities (MedDRA, www.
meddra.org). Missing values were not imputed.
3. Results
In 95 patients treatment with LEV-iv was started and their data
was included in the safety set. Two patients were excluded from
the efﬁcacy analysis due to lack of sufﬁcient seizure outcome data.
The remaining 93 patients were included into the analysis. Median
observation period was 10 days (range 1–376 days), median
treatment duration was 2 days (range 1–13 days). 56% of patients
had a LEV-iv treatment duration longer than 2 days.
Approximately half of patients were female, no woman was
pregnant. Median age was 66 years (range 0.7–90.3 years), 15% of
patients were children 16 years. In 59% of patients seizures were
diagnosed within the last 24 h before study entry, in 25% 2–30 days
before, 10% had a pre-existing epilepsy diagnosis longer than 30
days and only 6% for more than a year. Therefore, it can be
concluded that at approximately 60% of patients or more did not
have pre-existing epilepsy. Demographic data and baseline
characteristics are summarized in Table 1.
58 (62%) patients were diagnosed with focal seizures, 23 (25%)
patients had generalized seizures, and in 8 (9%) patients seizures
were non-classiﬁable (4 patients data not available). Aetiology was
most frequently cerebrovascular (41%), tumorous (10%) or infect-
related (9%). 15 patients (16%) had acute seizure clusters and 55
patients (59%) had conﬁrmed SE. Of those with SE, 41 patients
(75%) had SE for the ﬁrst time. Duration of SE before LEV-iv
Table 1
Patient characteristics.
Total 93 Patients
Female/male, n (%) 50/43 (54%/46%)
Mean age  SE 55  28 years
Median age (range) 66 (0.7–90) years
18 years 16 (17%)
19 to <50 years 14 (15%)
50 years 63 (68%)
Seizure type, n (%)
Generalized 23 (25%)
Focal 58 (62%)
Not classiﬁable 8 (9%)
Data not available 4 (4%)
Aetiology, n (%)
Cerebrovascular 38 (41%)
Dementia 5 (5%)
Infection 8 (9%)
Traumatic 7 (8%)
Residual situation 7 (8%)
Metabolic 3 (3%)
Genetic 4 (4%)
Tumour 9 (10%)
Toxic 5 (5%)
Malformation 3 (3%)
Others 23 (25%)
Status epilepticus, n (%) 55 (59%)
Seizure clusters, n (%) 15 (16%)
Duration of SE, n (%)
<24 h 22 (40%)
24–72 h 13 (24%)
>72 h 15 (27%)
Not available 5 (9%)
Table 3
LEV-iv doses (n = 93).
Dose per day (mg)
Mean  SE 1632  863
Median (range) 1500 (110–6000)
Duration of LEV-iv, n (%)
1 day 30 (32%)
2 days 19 (20%)
3–5 days 25 (27%)
>5 days 18 (19%)
Median (range) days 2 (1–13)
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SE patients and >72 h in 27% of SE patients.
Prior to the study 39 (42%) patients were treated with multiple
AEDs and 27 patients (29%) with psycholeptics. Table 2 shows all
drugs patients received at inclusion to the study. Of all patients
with status epilepticus 47% had received other pharmacological
treatment before LEV-iv was applied (41% benzodiazepines, 26%
other iv-antiepileptics and 2% anaesthetics). Of all 95 patients 21
were pretreated with oral levetiracetam and 3 patients had
already been treated with LEV-iv previously, thus 71 were naive to
LEV. Overall, 80 (86%) patients had at least one concomitant
disease, most frequently nervous system disorders (n = 44, 47%),
vascular disorders (n = 31, 33%) and/or metabolic disorders
(n = 23, 25%).
The main reasons for the introduction of LEV-iv (multiple
answers possible) were in 29 (31%) patients a non-convulsive SE
and in 18 (19%) patients convulsive SE. 18 (19%) patients had acute
seizures or seizure series, respectively. In 17 (18%) patients, comaTable 2
Concomitant drugs patients received at inclusion to the study
(total n = 93).
n (%)
Patients receiving at least 1 drug 80 (86%)
Antiepileptics 39 (42%)
Psycholeptics 27 (29%)
Diuretics 20 (22%)
Analgesics 19 (20%)
Renin–angiotensin inhibitors 18 (19%)
Antibacterial drugs for systemic use 17 (18%)
Antacids 17 (18%)
Ophthalmics 17 (18%)
Beta blocking agents 16 (17%)
Antithrombotics 13 (14%)
Corticosteroids for systemic use 10 (11%)
Psychoanaleptics 10 (11%)was documented as the main reason and in 21 patients other
reasons were predominant, such as anticonvulsive prophylaxis,
gastrointestinal reasons, planned surgery, or invasive examination.
In 78 patients the acute reason for seizures was known, most
frequently it was fever (11 patients), followed by encephalitis (4
patients) and dehydration (2 patients).
In 92 patients (99%) LEV was diluted in normal saline (in one
patient in Ringer-lactate solution) and administered through a
peripheral line. In 9 patients concomitant medication (analgetics,
antiepileptics or antipsychotics) was administered with the
infusion. The median dose of LEV-iv was 1500 mg (range 110–
6000 mg) per day. Median number of infusions was 4 per patient
(range 1–20) and median duration of treatment was 2 days (range
1–13 days) (Table 3). Mean daily dose was increased in 21 patients
(23%) and reduced in 18 patients (19%).
Cardiovascular parameters (systolic and diastolic blood pres-
sured, and pulse frequency) were documented in 81 patients (85%)
prior, in 63 patients during and in 67 patients after LEV-iv infusion.
Mean absolute values for systolic and diastolic blood pressure were
127/71 prior LEV-iv, 119/66 during LEV-iv and 123/69 after LEV-iv
(in mmHg). Mean absolute values for pulse frequency were 90
prior LEV-iv, 89 during LEV-iv and 88 after LEV-iv (in bpm). Mean
relative changes after LEV-iv compared to prior were 2% (SD 14%)
for systolic and +1% (SD 20%) for diastolic blood pressure, and +1%
(14%) for pulse frequency. Cardiovascular parameters were rated
abnormal in 2 patients prior LEV-iv, in 3 patients during LEV-iv,
and in one patient after LEV-iv.
Electrocardiograms were recorded in 62 prior LEV-iv, in 52
during, and in 49 after LEV-iv infusion. Prior to the LEV-iv infusion
5 patients showed abnormalities in ECG, but during and after
infusion no abnormality was found.
SE or seizure clusters could be terminated in 58 of 70 patients
(83%) in temporal relationship with LEV-iv administration. Overall
efﬁcacy of LEV-iv was rated by the physicians as ‘very good’ in 38
patients (41%), ‘good’ in 34 patients (37%), ‘satisfactory’ in 5
patients (5%), ‘sufﬁcient’ in 7 patients (8%) and ‘‘insufﬁcient’’ in 8
patients (9%, data of 1 patient not available). Patients self-assessed
efﬁcacy as ‘very good’ in 17 cases (39%), ‘good’ in 43 cases (19%),
‘satisfactory’ in 2 cases (1%), ‘sufﬁcient’ in 2 cases (5%) and
‘‘insufﬁcient’’ in 5 cases (11%, data of 49 patients not available).
A total of 29 treatment emergent adverse events (TEAEs) were
reported in 17 of the 95 patients from the safety set (72%) during
the observational period. Ten of these in 6 patients were at least
possibly related to LEV-iv treatment as judged by the physician
(Table 4). Slight decrease of blood pressure during the infusion was
captured most frequently (n = 3). In these patients the adverse
event was resolved by reducing the speed of infusion. All other side
effects (restlessness, fatigue, loss of appetite, cough, increased
upper airway secretion, infusion-related reaction, insufﬁcient
efﬁcacy) occurred only in one patient each. All side effects are
in line with the Summary of Product Characteristics of Keppra1.
Thirteen serious TEAEs (sTEAEs) occurred in 8 patients (8%).
Three patients (3%) died due to their basic diseases and two
patients had an aggravation of seizures. All other sTEAEs occurred
Table 4
TEAEs related to LEV-iv (n = 10 in 6 patients).
N
Decrease of blood pressure 3
Restlessness 1
Fatigue 1
Loss of appetite 1
Cough 1
Increased upper airway secretion 1
Infusion-related reaction, 1
Insufﬁcient efﬁcacy 1
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relationship to LEV-iv, as rated by the treating physicians.
Overall tolerability of LEV-iv was rated by the physicians as
‘very good’ in 46 patients (50%), ‘good’ in 42 patients (46%),
‘satisfactory’ in 2 patients (2%), ‘sufﬁcient’ in 1 patient (1%) and
‘insufﬁcient’ in 1 patient (1%, data of 1 patient not available).
Patients self-assessed tolerability as ‘very good’ in 15 cases (34%),
‘good’ in 23 patients (52%), ‘satisfactory’ in none, ‘sufﬁcient’ in 3
patients (7%) and ‘‘insufﬁcient’’ in 3 patients (7%, data of 49
patients not available).
Physicians rated overall handling of LEV-iv in 58 cases (67%) as
‘very easy’, in 25 cases (25%) as ‘easy’ and in 4 cases (5%) as
‘normal’. No one judged the handling as ‘difﬁcult’ or ‘very difﬁcult’
(data of 6 patients not available). After the LEV-iv period, 74
patients (80%) continued on oral levetiracetam. Of 71 (75%)
patients, that had been naı¨ve to LEV before the study, 47 (66%)
continued on oral levetiracetam. The adjustment from intravenous
to oral administration was rated as ‘very easy’ in 49 cases (63%),
‘easy’ in 25 cases (32%) and ‘normal’ in the remaining 4 patients
(5%, data of 15 patients not available).
In 14 patients (31%) treatment was discontinued during the
observational period. One patient discontinued due to an adverse
event (increased upper airway secretion). In three patients,
anticonvulsant response was considered insufﬁcient and LEV-iv
was discontinued. Two patients discontinued on their own request,
another patient was lost to follow up. The remaining 6 patients
discontinued due to adverse events related to their basic disease.
4. Discussion
This prospective non-interventional observational trial pre-
sents 95 patients in whom LEV-iv was administered. Most of them
were patients with acute status epilepticus at the time of
presentation. In 83% of patients, status epilepticus or seizure
clusters terminated after LEV-iv administration. Only mild,
transient side effects were observed.
It has been suggested that LEV-iv may be a safe and effective
therapy in the management of SE, although data to support this are
limited. In animal models, LEV-iv has been reported to abort SE, as
well as enhance the effect of diazepam, even when both were given
at subtherapeutic doses [10]. Evidence to support the use of LEV-iv
for SE in humans was initially limited to retrospective chart
reviews and case reports.
One of the ﬁrst reports of LEV as treatment in SE documented
termination of refractory SE in 3 of 12 patients (26%) under
treatment with oral LEV as add-on therapy [11]. Another report by
Rosetti and colleagues described the outcome of 23 patients who
received nasogastric LEV within 4 days of SE onset [12]. Ten of
these patients (43%) responded to a median dose of 2000 mg/day. It
was concluded that escalating the dosage beyond 3000 mg/day is
unlikely to provide an additional effect, and that early treatment
with LEV-iv leads to increased efﬁcacy compared to later
introduction of treatment.Additional case series followed and included patients with
repetitive seizures of different seizure types. Patel et al. described
six patients with complete cessation of SE 12–96 h after initiation
of oral LEV [13]. Knake et al. reported 18 episodes of SE in 16 adults,
which subsided after the addition of LEV-iv to the drug regimens
[14]. Berning et al. described termination of SE in 25 of 32 elderly
and multimorbid patients (78%) after administration of LEV-iv plus
benzodiazepines [15]. Similar responder rates after treatment with
LEV-iv were found by Gamez-Leyva et al. and Mo¨ddel et al.
reporting termination of SE in 71% of 43 patients, respective 69% of
36 patients [5,16]. As second-line treatment after unsuccessful use
of benzodiazepines LEV-iv had a success rate of 38/78 patients
without signiﬁcant adverse events [17]. LEV-iv was especially
effective in elderly patients with vascular SE, while cryptogenic SE,
primarily generalized SE and SE due to brain anoxia were
associated with poor response [16]. LEV-iv seems to be reasonably
tolerable even in multimorbid and critically ill patients, and even
when high dosages were applied within short time [15]. Another
study compared eight patients with non-convulsive SE in whom SE
was terminated by LEV-iv within 3 days in 11 patients treated with
conventional intravenous AED. The efﬁcacy was similar, but the
side-effects were much more severe with conventional AEDs [18].
Larger cohorts in adult patients basically conﬁrmed an useful risk-
beneﬁt ratio of LEV-iv [6,7,19]. Data to support LEV-iv use in
children with acute seizures or refractory SE are even more limited,
but in case reports and in observational studies LEV-iv has also
been reported to be an effective and safe adjuvant therapy in
children with refractory SE [20,21]. The established status
epilepticus trial (ESET) [22] was designed to compare the use of
fos-phenytoin, valproate and levetiracetam regarding their efﬁcacy
in treating SE among patients older than 2 years after the use of
benzodiazepines, and will possibly add further information to this
important topic.
Consistently with other studies, there were few side effects
reported, and none of them were considered as serious. There were
3 deaths within the observation time, representing 3% of study
population. However, all of these deaths could be attributed to the
underlying disease and were not related to the use of LEV-iv. This
suggests that LEV-iv has no signiﬁcant side effects and is well
tolerated in patient population of different ages, including children
and elderly. Also, it has no common cardiovascular side effects.
This prospective, observational study is limited by multiple
factors including its uncontrolled naturalistic design with an
inconsistent population, aetiology and semiology of seizures. Also,
there is missing or incomplete data for some of the patients.
However, it adds valuable information about the treatment of
patients with SE and difﬁcult to treat seizures or epilepsies in daily
practice. Efﬁcacy, tolerability and handling under routine practice
were rated in most patients as good or very good.
5. Conclusions
The present study demonstrates that LEV-iv shows favourable
qualities regarding efﬁcacy tolerability and handling for the use in
patients of different ages. Our study included a large number of
patients with SE. In these patients, similar results to retrospective
chart reviews were achieved supporting the use of LEV-iv as
alternative treatment option in SE. Large, prospective, randomized,
controlled studies are warranted to investigate the efﬁcacy and
safety of LEV-iv for the treatment of SE.
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